Difference between revisions of "Team:NTU-LIHPAO-Taiwan/Modeling"

 
(18 intermediate revisions by 2 users not shown)
Line 507: Line 507:
  
 
.Container_Article_Picture {
 
.Container_Article_Picture {
−
height: 280px;
+
height: 480px;
 
width: 100%;
 
width: 100%;
 
padding-top: 25px;
 
padding-top: 25px;
Line 624: Line 624:
 
list-style-type: decimal;
 
list-style-type: decimal;
 
margin-left: 0px;
 
margin-left: 0px;
−
padding-left: 20px;
+
padding-left: 50px;
 
}
 
}
  
 
ol.part2 li {
 
ol.part2 li {
−
padding-top: 5px;
+
padding-top: 3px;
−
padding-bottom: 5px;
+
padding-bottom: 3px;
 
}
 
}
  
Line 727: Line 727:
 
<div class="Slidemenu">
 
<div class="Slidemenu">
 
<ul>
 
<ul>
−
<li><div class=width_small><div id=Position_Now><a href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan">Home</a></div></div>
+
<li><div class=width_small><a href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan">Home</a></div>
 
</li>
 
</li>
  
Line 737: Line 737:
 
</li>
 
</li>
 
 
−
<li><div class=width_small span style="cursor:default"><a>Project</a></div>
+
<li><div class=width_small span style="cursor:default"><div id=Position_Now><a>Project</a></div></div>
 
<ul class="subs">
 
<ul class="subs">
 
<li><a href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Description">Description</a></li>
 
<li><a href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Description">Description</a></li>
Line 752: Line 752:
 
<li><a href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Basic_Part">Basic Parts</a></li>
 
<li><a href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Basic_Part">Basic Parts</a></li>
 
<li><a href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Composite_Part">Composite Parts</a></li>
 
<li><a href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Composite_Part">Composite Parts</a></li>
−
<li><a href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Part_Collection">Part Collection</a></li>
 
 
</ul>
 
</ul>
 
</li>
 
</li>
Line 778: Line 777:
 
<ul class="main-Content">
 
<ul class="main-Content">
 
<li>
 
<li>
−
<span class="title">Overview</span>
+
<span class="title">Modeling</span>
 
<ul class="sub-Content">
 
<ul class="sub-Content">
−
<li><a href="#First1">Pigout Versus Stay in Shape</a></li>
+
<li><a href="#First1">Introduction</a></li>
−
</ul>
+
<li><a href="#First2">Pathways</a></li>
−
</li>
+
−
<li>
+
−
<span class="title">Background</span>
+
−
<ul class="sub-Content">
+
−
<li><a href="#Second1">CPP-PYY</a></li>
+
−
<li><a href="#Second2">Nisin Selection</a></li>
+
−
<li><a href="#Second3">Suicide</a></li>
+
−
</ul>
+
−
</li>
+
−
<li>
+
−
<span class="title">Reference</span>
+
−
<ul class="sub-Content">
+
−
<li><a href="#Third1">Reference</a></li>
+
 
</ul>
 
</ul>
 
</li>
 
</li>
Line 835: Line 821:
 
</div>
 
</div>
 
<div class="Text3">
 
<div class="Text3">
−
<b>In the Modeling part, we tried to simulate the pathways of our designed probiotic <i>L. casei</i> and secreted CPP-PYY complex inside human body, from oral ingestion to final PYY releasing, respectively. The ultimate goal is to build the general formula, and to find out the suitable and optimal dose for Healthin, which hopefully exerts the beneficial and harmless effect for appetite suppression.</b> In general, after taking Healthin, some <i>L. casei</i> pass through stomach and reach human intestine. Within the transient colonization, these modified <i>L. casei</i> produce CPP-PYY complex, and with the help of TAT, the complexes penetrate through the small intestine epithelial cells into circulation system. The linker between the complex is cut by thrombin in the blood, thus releasing free PYY for circulation, which binds to Y2 receptor in the hypothalamus for controlling satiety feeling. Moreover, the suicide device and bacteria survival were also considered in the simulation for safety concern. Combining data obtained from experimental results and several literatures, we applied MATLAB for calculation and simulation. By analyzing the pathways of L. casei inside human body step by step, the ultimate dose could be determined from the general formula.
+
In the Modeling part, we tried to <b>simulate the pathways of our designed probiotic <i>L. casei</i> and secreted CPP-PYY complex inside human body</b>, from oral ingestion to final PYY releasing, respectively. The ultimate goal is to <b>build the general formula, and to find out the suitable and optimal dose for Healthin</b>, which hopefully exerts the beneficial and harmless effect for appetite suppression.
 +
</div>
 +
<div class="Text3">
 +
In general, after taking Healthin, some <i>L. casei</i> pass through stomach and reach human intestine. Within the transient colonization, these modified <i>L. casei</i> produce CPP-PYY complex, and with the help of TAT, the complexes penetrate through the small intestine epithelial cells into circulation system. The linker between the complex is cut by thrombin in the blood, thus releasing free PYY for circulation, which binds to Y2 receptor in the hypothalamus for controlling satiety feeling. Moreover, the suicide device and bacteria survival were also considered in the simulation for safety concern. Combining data obtained from experimental results and several literatures, we applied MATLAB for calculation and simulation. By analyzing the pathways of <i>L. casei</i> inside human body step by step, the ultimate dose could be determined from the general formula.
 
</div>
 
</div>
  
Line 846: Line 835:
 
         <li>Bacteria distribution</li>
 
         <li>Bacteria distribution</li>
 
         <li>CPP-PYY penetration efficiency</li>
 
         <li>CPP-PYY penetration efficiency</li>
−
         <li>Adsorption into bloodstream</li>
+
         <li>Absorption into bloodstream</li>
 
         <li>Thrombin cleavage efficiency</li>
 
         <li>Thrombin cleavage efficiency</li>
 
         <li>Healthin drug effect</li>
 
         <li>Healthin drug effect</li>
Line 855: Line 844:
 
</div>
 
</div>
 
<div class="Text3">
 
<div class="Text3">
−
Click on here to see our Simulation Strategy and Results.
+
<b>—></b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Modeling/Pathways"><b>[Click on here to see our Simulation Strategy and Results]</b></a>
 
</div>
 
</div>
 
<div class="Text3">
 
<div class="Text3">
−
Click on here for Conclusion and Application.
+
<b>—></b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="https://2015.igem.org/Team:NTU-LIHPAO-Taiwan/Modeling/Conclusion"><b>[Click on here for Conclusion and Application]</b></a>
 +
</div>
 +
<div class="Container_Article_Picture">
 +
<div class="Article_Picture">
 +
<img src="https://static.igem.org/mediawiki/2015/6/60/NTU-Modeling.gif" width="480px"/>
 +
<div class="Article_PictureText"><div class="Text_Picture">[Fig.2-1] Pathway of Healthin</div></div>
 +
</div>
 
</div>
 
</div>
  

Latest revision as of 13:15, 18 September 2015

NTU-LIHPAO-Taiwan

Modeling
Introduction
Noticing the problem of obesity growing in Taiwan, our team NTU-LIHPAO-Taiwan make efforts to improve a designed probiotic for oral peptide drug — “Healthin”. For preventing the side effects from commercial weight loss pills, as in our project design, the product CPP-PYY complex is produced by genetically modified Lactobacillus casei, which is orally ingested. TAT helps to penetrate through the villi, and the released PYY then binds to hypothalamus for appetite suppression.
In the Modeling part, we tried to simulate the pathways of our designed probiotic L. casei and secreted CPP-PYY complex inside human body, from oral ingestion to final PYY releasing, respectively. The ultimate goal is to build the general formula, and to find out the suitable and optimal dose for Healthin, which hopefully exerts the beneficial and harmless effect for appetite suppression.
In general, after taking Healthin, some L. casei pass through stomach and reach human intestine. Within the transient colonization, these modified L. casei produce CPP-PYY complex, and with the help of TAT, the complexes penetrate through the small intestine epithelial cells into circulation system. The linker between the complex is cut by thrombin in the blood, thus releasing free PYY for circulation, which binds to Y2 receptor in the hypothalamus for controlling satiety feeling. Moreover, the suicide device and bacteria survival were also considered in the simulation for safety concern. Combining data obtained from experimental results and several literatures, we applied MATLAB for calculation and simulation. By analyzing the pathways of L. casei inside human body step by step, the ultimate dose could be determined from the general formula.
Pathways
The pathways of the novel oral peptide drug Healthin consist of 5 parts, from intake through peptide release inside human body :
  1. Bacteria distribution
  2. CPP-PYY penetration efficiency
  3. Absorption into bloodstream
  4. Thrombin cleavage efficiency
  5. Healthin drug effect
By utilizing MATLAB, we built a model from these pathways to construct the general formula for determining the dose response.
—>     [Click on here to see our Simulation Strategy and Results]
—>     [Click on here for Conclusion and Application]
[Fig.2-1] Pathway of Healthin
Maintained by the iGEM team NTU-LIHPAO-Taiwan    ©2015 NTU-LIHPAO-Taiwan